VE202 not checked

Vedanta Biosciences, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“VE202 is a rationally defined, live biotherapeutic product for oral administration.”In the company’s words, NCT05370885 on ClinicalTrials.gov
Tested for
Ulcerative Colitis, Colitis, Ulcerative
Main trialPhase 2
“A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).”In the company’s words, NCT05370885 on ClinicalTrials.gov

Other drugs for Ulcerative Colitis

All 79 drugs for Ulcerative Colitis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Terminated 29 Aug 2025 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow VE202

Following is part of Solo: you see every change to VE202 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in